Abstract 164P
Background
Immune checkpoint inhibitors (ICI) were demonstrated to extend survival in patients with metastatic esophageal squamous cell carcinoma (ESCC). However, the role of ICI in locally advanced ESCC is not yet established. Herein, we conducted a retrospective study to evaluate the efficacy and safety of ICI plus neoadjuvant concurrent chemoradiotherapy (CCRT) for patients with locally advanced ESCC.
Methods
ESCC patients treated with neoadjuvant CCRT were retrospectively recruited into our study. Patients were classified into ICI-CCRT and CCRT according to regimens during CCRT. ICI-CCRT referred to ICI plus chemoradiotherapy while CCRT referred to chemoradiotherapy alone. Kaplan-Meier curves were estimated for recurrent-free survival (RFS) and overall survival (OS).
Results
A total of 150 patients were enrolled into our study, with 43 patients in ICI-CCRT and 107 patients in CCRT group. The median age was 58.5 years old of our patients and median follow-up period were 22 months. As for patients in ICI-CCRT, 33 patients received nivolumab plus CCRT and 10 patients received pembrolizumab plus CCRT. The median RFS was not reach (NR) versus 16.2 months in ICI-CCRT and CCRT group, respectively (p= 0.016). The median OS was not reach (NR) versus 20.0 months in ICI-CCRT and CCRT group, respectively (p= 0.002). The response rates were significantly higher in IC-CCRT, accounting for 74 % versus 65 % in ICI-CCRT arm and CCRT arm, respectively. Multivariate analysis showed ICI-CCRT was an independent predictor associated with survival. Grade 3/4 adverse events were comparable between each group.
Conclusions
Neoadjuvant ICI-CCRT is superior to CCRT for locally advanced ESCC patients with similar toxicity profiles. Further prospective studies are warranted to validate our conclusions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract